Skip to main content
    R

    Revolution Medicines Inc (RVMD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $166.87
    -5.42 (-3.15%)

    Market Cap: $37.27B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Revolution Medicines Inc (RVMD) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Revolution Medicines (RVMD) to earn -$8.30 per share in the fiscal year ending Dec 31, 2026, on revenue of $625.36M. Of 25 analysts, 24 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 14 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 25 ratings average 1.84, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 96% of the ratings.

    RatingAnalystsShare
    Strong Buy520.0%
    Buy1976.0%
    Hold14.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    25

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 224.6%.

    Fiscal year ending Dec 31, 2026
    -$8.30
    EPS consensus, revenue $625.36M
    Fiscal year ending Dec 31, 2027
    -$3.10
    EPS consensus, revenue $2.03B
    Next report
    Feb 23, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$8.30-$9.84 to -$7.1822$625.36M$395.10M to $832.60M19
    Dec 31, 2027-$3.10-$9.91 to $2.4923$2.03B$682.20M to $3.37B23

    Quarterly Estimates

    The EPS consensus rises from -$1.87 for the quarter ending Dec 31, 2026 to -$0.81 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.87-$3.46 to -$0.8525$227.96M$43.73M to $528.36M23
    Mar 31, 2027-$0.81-$2.35 to $0.3811$462.04M$137.00M to $685.00M10

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 26 upward and 2 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 2026141
    Fiscal year ending Dec 31, 2027121

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$9.56.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$8.30-$9.58-$9.62-$9.73-$9.56N/A
    Fiscal year ending Dec 31, 2027-$3.10-$5.76-$5.72-$5.95-$6.60N/A
    Quarter ending Mar 31, 2027-$0.81-$1.83-$1.84-$1.84-$1.90N/A

    Frequently Asked Questions About RVMD

    What is the RVMD stock forecast?

    Consensus analyst estimates put Revolution Medicines's EPS at -$8.30 for the fiscal year ending Dec 31, 2026, on revenue of $625.36M. The consensus rating from 25 analysts is Buy.

    How do analysts rate RVMD stock?

    Of 25 analysts covering Revolution Medicines, 5 rate it Strong Buy, 19 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from RVMD next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$8.30, with estimates from -$9.84 to -$7.18 from 22 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.10, with estimates from -$9.91 to $2.49 from 23 analysts.

    What revenue do analysts expect from Revolution Medicines next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $625.36M, with estimates from $395.10M to $832.60M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $2.03B, with estimates from $682.20M to $3.37B.

    How many analysts cover RVMD?

    25 analysts rate Revolution Medicines stock, and 22 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.